A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis

Osteopathic Medicine and Primary Care

Volumn 3, Issue , 2009, Pages

  Fendrick, A Mark ^a   Greenberg, Bruce P ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b BlueSpark Healthcare Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61649117551     PISSN: None     EISSN: 17504732     Source Type: Journal    
DOI: 10.1186/1750-4732-3-1     Document Type: Review

References (51)

1. Hungin AP Kean WF Nonsteroidal anti-inflammatory drugs: Overused or underused in osteoarthritis? Am J Med 2001, 110:8S-11S 10.1016/ S0002-9343(00)00628-8 11165988
2. Abramson SB Attur M Amin AR Clancy R Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis Curr Rheumatol Rep 2001, 3:535-541 10.1007/s11926-001-0069-3 11709117
3. Vane JR Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Bio 1971, 231(25):232-235 5284360
4. Willoughby DA Moore AR Colville-Nash PR COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease Lancet 2000, 355:646-648 10.1016/S0140-6736(99)12031-2 10696997
5. Burke A Smyth E FitzGerald GA Analgesic-antipyretic agents: pharmacotherapy of gout Goodman & Gilman's The Pharmacological Basis of Therapeutics New York: McGraw-Hill Brunton LL, Lazo JS, Parker KL 11 2006, 671-715
6. Uzan A The unexpected side effects of new nonsteroidal anti-inflammatory drugs Expert Opin Emerg Drugs 2005, 10:687-688 10.1517/14728214.10.4.687 16262557
7. FitzGerald GA Coxibs and cardiovascular disease N Engl J Med 2004, 351:1709-1711 10.1056/NEJMp048288 15470192
8. Sachs CJ Oral analgesics for acute nonspecific pain Am Fam Physician 2005, 71:913-918 15768621
9. Pendleton A Arden N Dougados M Doherty M Bannwarth B Bijlsma JW Cluzeau F Cooper C Dieppe PA Gunther KP Hauselmann HJ Herrero-Beaumont G Kaklamanis PM Leeb B Lequesne M Lohmander S Mazieres B Mola EM Pavelka K Serni U Swoboda B Verbruggen AA Weseloh G Zimmermann-Gorska I EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) Ann Rheum Dis 2000, 59:936-944 1753053 11087696 10.1136/ard.59.12.936
10. Pincus T Koch GG Sokka T Lefkowith J Wolfe F Jordan JM Luta G Callahan LF Wang X Schwartz T Abramson SB Caldwell JR Harrell RA Kremer JM Lautzenheiser RL Markenson JA Schnitzer TJ Weaver A Cummins P Wilson A Morant S Fort J A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee Arthritis Rheum 2001, 44:1587-1598 10.1002/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X 11465710
11. Pincus T Koch G Lei H Mangal B Sokka T Moskowitz R Wolfe F Gibofsky A Simon L Zlotnick S Fort JG Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): Two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis Ann Rheum Dis 2004, 63:931-939 1755088 15082468 10.1136/ard.2003.020313
12. Abramson SB Inflammation in osteoarthritis J Rheumatol Suppl 2004, 70:70-76 15132359
13. Bonnet CS Walsh DA Osteoarthritis, angiogenesis and inflammation Rheumatology (Oxford) 2005, 44:7-16 10.1093/rheumatology/keh344 15292527
14. Dray A Inflammatory mediators of pain Br J Anaesth 1995, 75:125-131 7577246
15. Creamer P Hochberg MC Osteoarthritis Lancet 1997, 350:503-508 10.1016/ S0140-6736(97)07226-7 9274595
16. Dieppe PA Lohmander LS Pathogenesis and management of pain in osteoarthritis Lancet 2005, 365:965-973 10.1016/S0140-6736(05)71086-2 15766999
17. Walker-Bone K Javaid K Arden N Cooper C Regular review: Medical management of osteoarthritis BMJ 2000, 321:936-940 1118736 11030685 10.1136/bmj.321.7266.936
18. Schiff M Minic M Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee J Rheumatol 2004, 31:1373-1383 15229960
19. Boureau F Schneid H Zeghari N Wall R Bourgeois P The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip Ann Rheum Dis 2004, 6:1028-1034 10.1136/ard.2003.011403
20. Golden HE Moskowitz RW Minic M Analgesic efficacy and safety of nonprescription doses of naproxen sodium compared with acetaminophen in the treatment of osteoarthritis of the knee Am J Ther 2004, 11:85-94 10.1097/00045391-200403000-00002 14999359
21. Moskowitz RW Osteoarthritis: Simple analgesics versus nonsteroidal antiinflammatory drugs J Rheumatol 2001, 28:932-934 11361218
22. Aleve product information Last update: 2008 Bayer HealthCare; Morristown, NJ http://www.rxlist.com Accessed April 7, 2008
23. Naproxen product information Last update: 2008 Roche Laboratories, Inc.; Nutley, NJ http://www.rxlist.com Accessed February 14, 2008
24. Bombardier C Laine L Reicin A Shapiro D Burgos-Vargas R Davis B Day R Ferraz MB Hawkey CJ Hochberg MC Kvien TK Schnitzer TJ Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 2000, 343:1520-1528 10.1056/NEJM200011233432103 11087881
25. Scheiman JM Fendrick AM Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs Arthritis Res Ther 2005, 7(Suppl 4):S23-S29 10.1186/ar1795 16168078
26. Fries JF Murtagh KN Bennett M Zatarain E Lingala B Bruce B The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis Arthritis Rheum 2004, 50:2433-2440 10.1002/ art.20440 15334455
27. Schnitzer TJ Burmester GR Mysler E Hochberg MC Doherty M Ehrsam E Gitton X Krammer G Mellein B Matchaba P Gimona A Hawkey CJ Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial Lancet 2004, 364:665-674 10.1016/S0140-6736(04)16893-1 15325831
28. Eisen G Lack of correspondence of risk factors and clinical GI outcomes for patients on nonsteroidal anti-inflammatory drugs (NSAIDs): Analysis from the Celecoxib Long-term Arthritis Safety Study (CLASS) Gastroenterology 2001, 120:A553
29. Silverstein FE Faich G Goldstein JL Simon LS Pincus T Whelton A Makuch R Eisen G Agrawal NM Stenson WF Burr AM Zhao WW Kent JD Lefkowith JB Verburg KM Geis GS Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 2000, 284:1247-1255 10.1001/ jama.284.10.1247 10979111
30. Chou R Helfand R Peterson K Dana T Roberts C Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review no. 4 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024.). Last update: September 2006 http://www.effectivehealthcare.ahrq.gov/reports/final.cfm Accessed April 7, 2008
31. Bresalier RS Sandler RS Quan H Bolognese JA Oxenius B Horgan K Lines C Riddell R Morton D Lanas A Konstam MA Baron JA Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 2005, 352:1092-1102 10.1056/NEJMoa050493 15713943
32. Solomon SD McMurray JJ Pfeffer MA Wittes J Fowler R Finn P Anderson WF Zauber A Hawk E Bertagnolli M Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 2005, 352:1071-1080 10.1056/NEJMoa050405 15713944
33. US Food and Drug Administration FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product FDA News. September 30, 2004. Last update: 2007 http://www.fda.gov/bbs/topics/news/ 2004/NEW01122.html Accessed August 15, 2007
34. Nussmeier NA Whelton AA Brown MT Langford RM Hoeft A Parlow JL Boyce SW Verburg KM Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery N Engl J Med 2005, 352:1081-1091 10.1056/NEJMoa050330 15713945
35. Arber N Eagle CJ Spicak J Racz I Dite P Hajer J Zavoral M Lechuga MJ Gerletti P Tang J Rosenstein RB Macdonald K Bhadra P Fowler R Wittes J Zauber AG Solomon SD Levin B Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 2006, 355:885-895 10.1056/NEJMoa061652 16943401
36. Kearney PM Baigent C Godwin J Halls H Emberson JR Patrono C Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials BMJ 2006, 332:1302-1308 1473048 16740558 10.1136/bmj.332.7553.1302
37. Catella-Lawson F Reilly MP Kapoor SC Cucchiara AJ DeMarco S Tournier B Vyas SN FitzGerald GA Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 2001, 345:1809-1817 10.1056/NEJMoa003199 11752357
38. Farkouh ME Greenberg JD Jeger RV Ramanathan K Verheugt FW Chesebro JH Kirshner H Hochman JS Lay CL Ruland S Mellein B Matchaba PT Fuster V Abramson SB Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib Ann Rheum Dis 2007, 66:764-770 10.1136/ard.2006.066001 17412741
39. Gaziano JM Gibson CM Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection Am J Cardiol 2006, 97:23-29 10.1016/ j.amjcard.2006.02.020 16675319
40. Advil product information Last update: 2008 Wyeth Consumer Healthcare; Madison, NJ http://www.advil.com/products/advil/tablet_label.asp Accessed February 14, 2008
41. Capone ML Sciulli MG Tacconelli S Grana M Ricciotti E Renda G Di Gregorio P Merciaro G Patrignani P Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J Am Coll Cardiol 2005, 45:1295-1301 10.1016/j.jacc.2005.01.045 15837265
42. Brune K Hochberg M Schiff M Oldenhof J Schuller R Zlotnick S The platelet inhibitory effects of the combination of naproxen sodium or acetaminophen with low-dose aspirin Arthritis and Rheumatism 2007, 56:S359
43. Zlotnick S Oldenhof J Schuller R Hochberg MC Schiff M Effect of over-the-counter doses of naproxen sodium on inhibition of platelet cyclooxygenase-1 in healthy volunteers [poster L33] Presented at the 70th Annual Meeting of the American College of Rheumatology, Washington DC, November 11, 2006
44. Zhang W Moskowitz RW Nuki G Abramson S Altman RD Arden N Bierma-Zeinstra S Brandt KD Croft P Dohert M Dougados M Hochberg M Hunter DJ Kwoh K Lohmander LS Tugwell P OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines Osteoarthritis Cartilage 2008, 16:137-162 10.1016/ j.joca.2007.12.013 18279766
45. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update Arthritis Rheum 2000, 43:1905-1915 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P 11014340
46. Hochberg MC Altman RD Brandt KD Clark BM Dieppe PA Griffin MR Moskowitz RW Schnitzer TJ Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology Arthritis Rheum 1995, 38:1541-1546 10.1002/art.1780381104 7488273
47. Simon LS Lipman AG Jacox AK Caudill-Slosberg M Gill LH Keefe FJ Kerr KL Minor MA Sherry DD Vallerand AH Vasudevan S Pain in osteoarthritis, theumatoid arthritis and juvenile chronic arthritis Glenview, Illinois: American Pain Society 2 2002
48. Scheiman JM Fendrick AM Summing the risk of NSAID therapy Lancet 2007, 369:1580-1581 10.1016/S0140-6736(07)60722-3 17499583
49. Lewis JD Kimmel SE Localio AR Metz DC Farrar JT Nessel L Brensinger C McGibney K Strom BL Risk of serious upper gastrointestinal toxicity with over-the-counter nonaspirin nonsteroidal anti-inflammatory drugs Gastroenterology 2005, 129:1865-1874 10.1053/j.gastro.2005.08.051 16344055
50. Scheiman JM Yeomans ND Talley NJ Vakil N Chan FK Tulassay Z Rainoldi JL Szczepanski L Ung KA Kleczkowski D Ahlbom H Naesdal J Hawkey C Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors Am J Gastroenterol 2006, 101:701-710 10.1111/j.1572-0241.2006.00499.x 16494585
51. US Food and Drug Administration. April 1, 2007. Internal analgesic, antipyretic, and antirheumatic drug products for over-the counter human use http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=343.80 Accessed May 16, 2008